{"preliminary_commentary":{"by_channel":{"bluesky_thread":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05468489","nct_id":"NCT05468489","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05468489. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Serplulimab + chemotherapy (carboplatin-etoposide)","label":"Serplulimab + chemotherapy","type":"EXPERIMENTAL"},{"description":"Atezolizumab + chemotherapy (carboplatin-etoposide)","label":"Atezolizumab + chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Extensive Stage Small Cell Lung Cancer"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Serplulimab + chemotherapy (carboplatin-etoposide)","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab + chemotherapy (carboplatin-etoposide)","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-21","lead_sponsor":"Shanghai Henlius Biotech","official_title":"A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"OS","timeFrame":"A period from randomization through death regardless of causality (approximately up to 24 months)."}],"references":[],"start_date":{"date":"2022-11-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","url":"https://clinicaltrials.gov/study/NCT05468489"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05468489"}